ERBB2 and breast carcinoma: The statistical analysis indicated that triple-positive patients were slightly younger at the time of breast cancer diagnosis (median 50 years versus 53 years; P = 0.023), had a smaller tumor size (breast cancer <5 cm 78% versus 67%; P = 0.003) and a lower rate of differentiation of the primary tumor (G3 tumor differentiation in 53% versus 70%; P < 0.001) than HER2-positive/hormone receptor-negative patients.